SCHEMBL6019337

SCHEMBL6019337

CN(C[C@H]1CC[C@H](CO)CC1)C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.43
CNR2 P34972 1/20 0.35
ASGR1 P07306 1/20 0.34
LIMK2 P53671 1/20 0.33
KMT2A Q03164 1/20 0.33
HTR2C P28335 4/20 0.32
SLC6A4 P31645 4/20 0.32
PTGIR P43119 1/20 0.32
SPR P35270 1/20 0.32
ALOX5 P09917 1/20 0.32
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
HTR2A P28223 1/20 0.31
FPR3 P25089 1/20 0.31
FPR2 P25090 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
CTSS P25774 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6019334 1.00 NR1H2 (0.43) NR1H2CNR2ASGR1LIMK2KMT2A
SCHEMBL15017085 0.93 CNR2 (0.38) NR1H2CNR2ASGR1LIMK2KMT2A
SCHEMBL25568402 0.87 NR1H2 (0.36) NR1H2CNR2ASGR1LIMK2KMT2A
SCHEMBL31295083 0.87 NR1H2 (0.46) NR1H2ASGR1HTR2CSLC6A4SPR
SCHEMBL25568400 0.87 NR1H2 (0.36) NR1H2CNR2ASGR1LIMK2KMT2A
SCHEMBL24438464 0.86 ALOX5 (0.39) CNR2ASGR1LIMK2HTR2CSLC6A4
SCHEMBL6019184 0.86 CNR2 (0.35) NR1H2CNR2ASGR1LIMK2KMT2A
SCHEMBL6019187 0.86 CNR2 (0.35) NR1H2CNR2ASGR1LIMK2KMT2A
SCHEMBL6018562 0.86 TDP1 (0.37) NR1H2CNR2ASGR1LIMK2KMT2A
SCHEMBL6018558 0.86 TDP1 (0.37) NR1H2CNR2ASGR1LIMK2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456171-B1 SUBSTITUTED CYCLOHEXANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-12-20 EP disclosed
US-20050272774-A1 Substituted cyclohexane derivatives ACKERMANN JEAN 2005-12-08 US disclosed
US-6953806-B2 Substituted cyclohexane derivatives HOFFMANN-LA ROCHE INC. (US) 2005-10-11 US disclosed
EP-1456171-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-09-15 EP disclosed
US-20030199550-A1 Substituted cyclohexane derivatives F.HOFFMANN-LA ROCHE AG (CH) 2003-10-23 US disclosed
WO-2003053919-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272774-A1 Substituted cyclohexane derivatives LSS, CYP51A1, CYP8B1 NR1H2 47/4885CNR2 496/4885ASGR1 885/4885
US-20030199550-A1 Substituted cyclohexane derivatives CYP51A1, LSS, CYP46A1 NR1H2 22/4885CNR2 547/4885ASGR1 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.